Multicentre Research Projects only - ACCEPTING SITE GUIDANCE when GC HREC is <u>NOT</u> the Reviewing HREC Documents sent to the Gold Coast HREC vs. the Gold Coast RGO: Summary of Institutional Procedures - Guide for Researchers

Underlying Principle:

1. The Human Research Ethics Committee (HREC) undertakes the scientific and ethical review of a study.

2. The Research Governance Office (RGO) reviews the financial, resources, contractual and regulatory aspects of undertaking the research at the site.

3. Site specific negotiations and completion of the SSA form should commence as soon as or before the HREC Application has been submitted. Site will not receive the formal Authorisation Letter to commence the study until the HREC Approval letter is presented to the RGO.

4. Institutional/Governance authorisation or acknowledgment must be received before a study can start or an amendment to the PICF study can be implemented.

5. All documents ideally would be uploaded onto AU-RED. This ensures paper copies of documents do not need to be submitted to the RGO unless specified below.

Document	Paperwork to be sent to the GC HREC	Type of Letter from GC HREC to Accepting Site	Paperwork to be sent to the GC RGO when the Reviewing HREC is NOT at the same site as GC RGO	Type of Letter from GC RGO	Do I need to wai for the GC RGO letter?	
Ethics Application form (NEAF / LNR)	×	NA	\checkmark	Authorisation Letter	Yes	
Protocol	×		✓			
Investigator Brochure	*		✓			
PICF – Master Copy (with version control)	*		✓			
Assessment Tools	×		(Only if tool contains site specific information or identifiers)			
Patient tools e.g. diary, wallet card, brochures, advertising	×		 (Only if tool contains site specific information or identifiers) 			
Advertisements	×		 (Only if advertisement contains site specific information or identifiers) 			
CTN / CTX Form	×		(to be submitted on line from 01.07.2015)			
HREC Review Only Indemnity	×		×			
In addition to the items listed above, the following	ng form part of the sit	e specific application to	o obtain authorisation to commence research:			
SSA and cover letter/form to RGO	*	NA	✓			
HREC Approval Letter	*		✓	All documentation submitted with the initial applicati for site authorisation must be noted in the Site "Authorisation to Commence Research" letter. The project at the site cannot start until the RGO		
PICFs – Site Specific (tracked and clean with version control)	×		✓			
Clinical Trial Research Agreement (CTRA)	×		✓			
Insurance Certificate	×		✓	Authorisation Letter is issued.		
Site Specific Standard Indemnity	×		✓			

After Study Authorisation - ACCEPTING SITE GUIDANCE when GC HREC is NOT the Reviewing HREC									
	Document ¹	Paperwork to be sent to the GC HREC	Type of Letter from GC HREC to Accepting Site	Paperwork to be sent to the GC RGO when the Reviewing HREC is NOT at the same site as GC RGO	Type of Letter from GC RGO	Do I need to wait for the GC RGO letter?			
ENT	Protocol Amendments ² that pose NO CHANGE to the institutional risk or resource requirements ³	×	NA	\checkmark	The amendment can be implemented at the site after HREC approval is	No			
AMENDMENT	Protocol Amendments ² that DO POSE A CHANGE to the institutional risk or resource requirements ³	×	NA	~	Authorisation Letter The amendment can not be implemented until GC RGO approval is given	Yes			
	HREC Approval letter of Protocol Amendment to GC RGO	×	NA	✓	NA	NA			
PICF	Amended Multi-Centre Master PICF (with version control)	×	NA	✓	NA	Yes			
	Amended Site Specific PICFs (for multi-centre studies where the Master PICF is changed) – (tracked and clean with version control)	×	NA	✓ 2	Authorisation Letter Site specific PICF cannot be used until RGO Authorisation Letter is received.	Yes			
	CTRA - amendment	×	NA	✓	Signed CTRA	No			
_	CTN / CTX Form - amendment	*	NA	(to be submitted on line from 01.07.2015)	NA	No			
GAL	HREC Review Only Indemnity – amendment	×	NA	*	NA	No			
LEG	Site Specific Standard Indemnity - amendment	×	NA	✓	Signed Indemnity	No			
	Updated Insurance Certificate	×	NA	✓	Acknowledgement Email	No			
	Investigator Brochure - amendment	×	NA	*	NA	No			
	SAEs - On-site ⁴ commercial studies	×	NA	✓ 4	Acknowledgement Email	No			
SAFETY	SAEs - On-site ⁴ investigator initiated studies	×	NA	✓ 4	Acknowledgement Email	No			
AF	12 monthly line listings and Safety Reports ⁵	×	NA	≵ 5	NA	No			
0	DSMB Reports / Letters	*	NA	×	NA	No			
	Protocol Deviations/Violations ⁶	×	NA	√ 6	Acknowledgement Letter	No			
S	Commencement Form	*	NA	\checkmark	Acknowledgement Email	No			
REPORTS	Annual Reports (or more frequently depending on HREC approval) ⁷	×	NA	√7	Acknowledgement Email	No			
R	Study or Site Closure/Suspension	×	NA	✓	Acknowledgement Letter	No			
	General correspondence (e.g. memos that impact on the study - e.g. clarification of inclusion / exclusion criteria)	×	NA	×	NA	No			
OTHER	Change of Address of Sponsor (Australia sponsor/address only requires submission)	×	NA	✓	Acknowledgement Email	No			
	Any other documents not listed	×	NA	Please check with the RGO office before submission	Acknowledgement Letter	No			

After Study Authorisation - ACCEPTING SITE GUIDANCE when GC HREC is NOT the Reviewing HREC

Please note this document only applies to GC RGO procedures when the Reviewing HREC is NOT the GC HREC. Therefore if the Reviewing HREC is in Victoria and if GC is an Accepting Site then this document pertains to GC it is an Accepting Site within GC RGO jurisdiction.

2Protocol Amendment approvals will be sent to you from the study's CPI. A copy of the Protocol Amendment and Reviewing HREC approval letter must be sent to the GC RGO. The amendment can be implemented once the CPI provides the GC PI with

the Reviewing HRECs approval letter for that amendment, however if the amendment poses a change in institutional risk or increased resources then the site MUST obtain GC RGO approval prior to implementing the amendment.

f the amendment requires a change to the Master PICF then GC RGO approval for the Site-Specific PICF must be received before the patient specific changes can be implemented.

3Examples of Risk to the Institution are new unapproved data is to be collected and/or sent off site; or collection of extra tissue samples. Examples of Resource Implications are protocol requirements for extra visits, extra procedures or involvement of other

lepartments not previously approved (e.g. Radiology). These examples are not an exhaustive list.

Per NHMRC Safety monitoring and Reporting in clinical trials involving therapeutic goods

NOTATIONS The On-Site SAEs that must be submitted to the GC RGO are – Signifigant Safety Issues (SSIs); Unexpected & Related Serious Adverse Event (URSAEs) occurring at the site

For investigator-initiated studies submission of ALL On-Site SAEs to GC RGO is required.

5At an Accepting Site no submissions of any safety reports are required to GC RGO. PI to initial, dates and file in site folder

6Violations and/or deviations must be submitted to the Reviewing HREC as per their guidelines. Violations need to be submitted to GC RGO as outlined in the table. Definition of a violation at Gold Coast is where patient safety is

compromised (e.g. signing an unapproved PICF, enrolment of an inappropriate patient into the trial; a dosing, timing or delivery error in the study intervention attributable to members of the research team; the research team failed to

comply with pre-specific trial guidelines for data collection and/or outcome evaluation due to avoidable reasons). Deviations do not reguire to be submitted (e.g. late study visits unless patient safety is compromised, deviation affects the

ethical acceptability of the study, medical or clinical assessment is missed) to either GC HREC or GC RGO.

In accordance with the Reviewing HREC requirements the CPI will advise re the requirements for submission Annual Reports.

Annual reports to be submitted 1 May every year.

Accepting PI: A Principal Investigator from an Accepting Site who is participating in the study but does not have the CPI responsibilities. Accepting Site: A site that is participating in a multi-centre research project, but which has not taken on CPI responsibility. Coordinating Principal Investigator (CPI): The CPI Team from the Lead Site is responsible for coordinating all HREC processes throughout the study, on behalf of the Accepting PI's over which CTN: Clinical Trial Notification **CTRA:** Clinical Trial Research Agreement CTX: Clinical Trial Exemption DSMB: Data Safety Monitoring Board GLOSSARY HREC: Human Research Ethics Committee Lead Site: A site that is participating in a multi-centre research project and has taken on CPI responsibility. Multi-Centre Research: A research project undertaken by a group of institutions (or individuals) at one or more sites within and/or across Australian jurisdictions. GC: Gold Coast NEAF: National Ethics Application Form PI: Principal Investigator = PI for an Accepting Site in Multi-Centre Research; PI for Single-Site Research PICF: Participant Informed Consent Form Reviewing HREC: For multi-centre research, the reviewing HREC is NHMRC certified which, under the single ethical review process, has reviewed and ethically approved the study and has assumed responsibility for RGO: Research Governance Office SAE: Serious Adverse Event Single-Site Research: A research project undertaken at only one site.